Uso apropiado de DAI Resincro

•Download as PPTX, PDF•

0 likes•168 views

The document discusses guidelines for the appropriate use of cardiac resynchronization therapy (CRT) according to the ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 criteria. CRT is assigned a score between 1 and 9, with 7-9 indicating appropriate use, 4-6 indicating may be appropriate, and 1-3 indicating rare appropriate use. The document provides the criteria scores for various patient conditions and indications for CRT.

Health & Medicine

Indicaciones de uso apropiado
de DAI – Resincronizador
Dr. Miguel Ayala León
Residente de tercer año de cardiología

Figura 1
ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada
ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

- Antibiotics are given to prevent and treat infections. - The driveline exit site is cleaned and dressed regularly. - If infection occurs inside the body, removal of the device may be required followed by long term antibiotics. - Prevention of infection is the key - cleanliness of the exit site, prophylactic antibiotics etc. are important. 4) Bleeding: - Patients need to take blood thinning medications like warfarin to prevent clots. This increases the risk of bleeding. - Bleeding can occur from the exit site, during surgery or internally. It needs immediate medical attention. - Blood transfusions may be required to replace lost blood volume.

LVAD - Left Ventricular Assist Device

Vishal Vanani

A Closer Look at LVAD

Ruthie Cavales

This presentation provides information on left ventricular assist devices (LVADs) and the associated nursing implications. LVADs are mechanical pumps that can be used as a bridge to heart transplantation, to aid in heart recovery, or as destination therapy for end-stage heart failure patients. The presentation discusses the components and types of LVADs, how they work, important functions for nurses to understand, potential complications, critical alarms, and end-of-life considerations for patients with LVADs. It emphasizes the increasing need for nurses to be trained on caring for the growing LVAD patient population.

Development of an Axial Flow Left Ventricular Assist Device (LVAD) from Incep...

tmhsweb

1. The document discusses the development and clinical applications of axial flow left ventricular assist devices (LVADs) from their inception to help treat the increasing number of heart failure patients. 2. It describes the history and outcomes of various LVAD models used at the Methodist Hospital including the DeBakey-Noon VAD which was licensed from NASA and has been implanted in over 400 patients internationally. 3. The document outlines ongoing engineering improvements to LVAD designs through computational fluid dynamics and animal testing, including a smaller pediatric version, to provide longer and better quality of life support for heart failure patients.

WATCHMAN TRIAL

Praveen Nagula

The PREVAIL trial assessed the safety and efficacy of left atrial appendage (LAA) occlusion using the WATCHMAN device compared to long-term warfarin therapy for stroke prevention in patients with nonvalvular atrial fibrillation. The trial found that at 18 months, LAA occlusion was noninferior to warfarin for the secondary efficacy endpoint of stroke or systemic embolism over 7 days post-randomization. However, noninferiority was not achieved for the primary efficacy endpoint which was a composite of stroke, embolism, and death. Procedure-related safety events were significantly lower than in prior trials. The trial demonstrated that LAA occlusion is a reasonable alternative to warfar

J. cleveland destinatin lvad therapy are we there yet

Alysia Smith

Left ventricular assist devices

patacsi

The document discusses left ventricular assist devices (LVADs), which are mechanical pumps that help the failing left ventricle pump blood to the body. It provides background on the history and development of LVAD technology, describing early models and milestones as well as current FDA-approved devices like the HeartMate II. The document also outlines how LVADs work, their uses as either a bridge to transplant or for destination therapy, and outcomes data from clinical trials.

Dr. Raphael Rosso — The Watchman Left Atrial Appendage Occluder: Where do we ...

Pavel Fedotov

1) The document discusses the Watchman left atrial appendage occluder device as an alternative to warfarin for stroke prevention in atrial fibrillation. 2) Data from the PROTECT AF trial showed the device was noninferior to warfarin for preventing strokes and had a lower risk of hemorrhagic strokes. 3) Subsequent studies demonstrated high rates of successful implantation across trials, ranging from 90.9-95.1%, and a learning curve effect with lower adverse events over time.

Fortis Memorial Research Institute is a large multi-specialty hospital. The document describes the catheterization lab (cath lab) workflow, including patient admission, financial counseling, coordination with insurance approvals, discharge process, and data record keeping. It provides tips to reduce turnaround times for procedures like sending insurance documents directly to the cath lab. The project involved learning the cath lab work flow, improving efficiency, and supporting patients and doctors.

Vad presentatioin

EMSMedic79

A ventricular assist device (VAD) is a mechanical pump that is surgically implanted to assist one or both failing ventricles of the heart. It helps pump blood to the body when the heart is too weak. Complications can include bleeding, infection, device malfunction. Proper management focuses on maintaining adequate blood volume and flow through the device. Transporting VAD patients requires bringing all equipment and contacting the implanting center for guidance.

LVADS

Anirudh Allam

Left ventricular assist devices (LVADs) are mechanical pumps that are used to support heart function in patients with heart failure. There are several indications for LVAD support including bridging patients to cardiac transplantation, bridging to decision about transplantation eligibility, as destination (permanent) therapy for those ineligible for transplantation, and bridging to potential heart recovery. LVADs improve symptoms and survival in advanced heart failure patients and can allow some to recover enough to no longer require support or become eligible for transplantation. Newer continuous flow LVAD designs have improved outcomes compared to older pulsatile devices.

16:05 Bufe - Learning to stop and to stage CTO PCI

Euro CTO Club

1) The document discusses strategies for percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs), including staged procedures and when to stop a procedure. 2) It notes that in cases of failed antegrade PCI, patients should be referred to a CTO specialist center for a second attempt, either immediately with a retrograde approach or in a staged procedure later. 3) Successful CTO recanalization rates have increased in recent years with more use of retrograde approaches, either primarily or after failed antegrade attempts. However, radiation exposure, contrast volume, and complications should be considered in determining when to stop a procedure.

Lvad vijayanand

Vijay Anand

This document discusses left ventricular assist devices (LVADs) including: - Types of LVAD support including bridge to transplantation, destination therapy, and devices like the HeartMate II. - Contraindications and patient criteria for LVAD support. - Components and functions of the LVAD including the external controller. - Monitoring of pump parameters on the controller. - Potential complications of LVAD support. - Clinical trial results demonstrating improved survival and quality of life with LVADs.

Protect Af Holmes2

hospital

The PROTECT AF trial was a randomized controlled trial comparing percutaneous left atrial appendage closure using the WATCHMAN device versus long-term warfarin therapy for stroke prevention in patients with non-valvular atrial fibrillation. The trial found that the device was non-inferior to warfarin for preventing all strokes and deaths, and superior for preventing hemorrhagic strokes. The device was associated with early safety events such as pericardial effusions that decreased over time, and most patients were able to stop warfarin within 45 days of the procedure. The trial demonstrated that the WATCHMAN device offers a safe and effective alternative to long-term warfarin therapy in appropriate patients

Lvad

Raja Lahiri

A ventricular assist device (VAD) is a mechanical pump that helps the ventricles pump blood through the body. VADs are used to treat heart failure and cardiogenic shock. They can partially or completely replace the function of a failing heart. VADs are designed to assist the right ventricle, left ventricle, or both ventricles. Common uses of VADs include bridging patients to transplant, bridging to recovery or decision, and destination therapy for patients who are not eligible for transplant. Complications of VAD therapy include bleeding, infection, thromboembolism, device malfunction, and right heart failure.

Application of MCS for the Treatment of Advanced Heart Failure

faminteractive

This document contains the slides from a presentation on Mechanical Circulatory Support (MCS) for advanced heart failure. It discusses the growing problem of heart failure, current treatment options and their limitations, and the role that MCS can play through strategies like Bridge to Transplant and Destination Therapy. It highlights improvements in continuous-flow LVADs like the HeartMate II that have increased survival for bridge to transplant patients. However, it notes that heart transplantation will never meet demand due to limited organ availability, and MCS provides an important alternative for patients who are not transplant candidates.

Mechanical circulatory support

Hristo Rahman

This document discusses mechanical circulatory support devices (MCSDs) and artificial hearts. It begins by explaining heart failure and its stages. It then describes various types of temporary and permanent MCSDs, including their goals, energy sources, blood flow characteristics, and implantation methods. Examples of specific MCSDs are provided like the IABP, ECMO, Impella, TandemHeart, HeartMate XVE, HeartMate II, HeartWare, Jarvik 2000, and total artificial hearts from SynCardia and Carmat. Major complications of MCSDs and artificial hearts discussed are bleeding, infection, and thrombosis.

Understanding the Translational Value of PV Loops from Mouse to Man

InsideScientific

In this exclusive webinar sponsored by Millar, Dr. Navin Kapur, Assistant Professor and Assistant Director of the Interventional Cardiology Center at Tufts Medical Center, discusses how PV loop data can translate over from mouse to man and provide a confident approach to evaluating drug studies, device validation and treatments outcomes. Hemodynamics and measurements of cardiac function from the research bench-top are presented along with findings from the clinical research settings. Furthermore, Dr. Kapur provides perspective on how PV Loops can be used as a tool for the interventional cardiologist and during the evaluation of advanced heart failure. Dr. Navin Kapur's research interests include the molecular basis of cardiac fibrosis, transforming growth factor-beta signaling in cardiac fibroblasts, and novel imaging modalities of myocardial perfusion.

The artificially prepared heart

Naveen Dasarapu

The document discusses artificial hearts as a treatment for heart failure. It describes the causes and symptoms of heart failure and explains how artificial hearts can replace a biological heart that is no longer functioning properly. There are two main types of artificial hearts - ventricular assist devices (VADs) that support one or both ventricles, and total artificial hearts (TAHs) that fully replace the entire biological heart. Artificial hearts can prolong life for those awaiting a heart transplant or act as a permanent replacement if a transplant is not possible. While artificial hearts have risks like infection, they allow patients with severe heart failure to survive until they can receive a donor heart.

Ventricular Assist Devices

SMACC Conference

Dr Priya Nair is a senior intensive care specialist at Sydney's St Vincent's Hospital and an expert in managing patients with cardiac assist devices. In this talk she takes us through the key issues encountered when on managing patients with left ventricular assist devices. As LVADs are becoming more widespread, this inside know-how is invaluable to all of us. They physiology and technology involved with these devices is pretty amazing. This is the second of two talks at the recent Sydney Intensive Network Meeting. The first talk was by Cardiologist Chris Hayward here.

Outcomes of left ventricular assist device implantation stratifiedby psychoso...

Andri Andri

This document summarizes a presentation on cognitive impairment in advanced heart failure patients undergoing left ventricular assist device (LVAD) implantation. It discusses that cognitive impairment is common in heart failure patients, affecting up to 75% of patients, and is associated with worse outcomes like increased mortality. The causes of cognitive impairment in heart failure include cerebrovascular changes from hypoperfusion and autonomic dysfunction leading to reduced brain volume and infarcts. The presentation aims to discuss how LVAD implantation may impact the cognitive trajectory of advanced heart failure patients.

Ventricular assist devices

degnarog

Ventricular assist devices (VADs) are mechanical pumps that help the failing heart pump blood. They can be used as a bridge to transplantation, destination therapy for those not eligible for transplant, or as a bridge to recovery or decision. VADs range from short-term percutaneous devices to long-term implantable devices. Long-term devices include pulsatile flow, axial continuous flow, and total artificial hearts. Selection depends on duration of support needed, whether right or left ventricular support is required, and the patient's prognosis and treatment goals. Implantation requires open-heart surgery and postoperative management focuses on prevention of complications like bleeding, infection, and thromboembolism.

Ventricular assist devices

Ela Maran

Ventricular assist devices (VADs) are mechanical pumps that help the failing heart pump blood. There are two main types - pulsatile VADs that pump blood in pulses and continuous flow VADs that pump blood continuously. VADs are used as a bridge to heart transplant, to help the heart recover, or as destination therapy for those not eligible for transplant. They are implanted using cardiopulmonary bypass to connect the inflow cannula in the left ventricle to the outflow cannula in the aorta. VADs improve heart function and quality of life for patients with heart failure.

Advanced Cardiovascular Surgery Hybrid Operating Room (Nuts & Bolts)

Jacques Kpodonu,MD

1) The document discusses the key factors for building an advanced cardiovascular hybrid operating room, including clinical requirement assessment, planning, project management, and partner management. 2) Some of the main considerations for a hybrid OR layout are ensuring adequate space for imaging equipment, surgical equipment, anesthesia equipment, and radiation shielding. Workflow for medical staff and patients must also be considered. 3) Building a hybrid OR requires defining roles and responsibilities, deciding on equipment, and iterative planning and verification between all involved parties to ensure needs are met. Total investment for a hybrid OR project can be over $6 million.

Nwater machanical ovel assist devices

drucsamal

Randall Starling discussed novel and emerging assist devices for advanced heart failure. These include fully magnetically levitated devices like the HeartMate III, partial support devices like the CircuLite Synergy pump, and techniques like aortic counterpulsation and an interatrial shunt to decompress the left atrium. Starling believes that left ventricular assist devices will continue to evolve and improve, allowing for their use in less ill patients to potentially support cardiac recovery.

RVADs/LVADs and all things mechanical by Dr Jayshree Lavana

CICM 2019 Annual Scientific Meeting

Survival in patients with advanced heart failure (AHF) has improved over the last 2 decades. An increasing number of patients however, are dying with progressive heart failure over the same duration. Optimal utilization of medical therapies and devices like implantable defibrillators and biventricular pacemakers are the likely reasons patients are surviving longer albeit with progressive HF. Evolution in mechanical circulatory support (MCS) devices has occurred over the same period, such that they can now be rapidly instituted providing support for pump failure, often percutaneously, with timely restitution of physiologic and metabolic derangements with fewer complications. MCS devices can be classified as Short term and Long term. Short term devices such as Intraaortic balloon pumps (IABP), Impella ®, TandemHeart® or Venoarterial extracorporeal membrane oxygenation (VA – ECMO) using a Cardiohelp® device, are usually employed as ‘Bridge to Recovery’(BTR) or Bridge to Decision’(BTD), usually in acute settings. Long term devices such as implantable left ventricular assist devices (LVADs) e.g. Heartmate II® & 3®, Heart ware HVAD® are implanted as ‘Bridge to transplant’ (BTT) or ‘Destination therapy’ (DT) usually in patients ‘sliding’ on inotropes when they are transplant eligible (BTT) or ineligible (DT) respectively. Ventricular assist devices have traditionally been developed for left ventricular support in case of severe left heart or biventricular dysfunction. Historically, right ventricular (RV) dysfunction following LVAD implantation or as a component of biventricular dysfunction was managed with either medical therapy, temporary VADs (i.e. ECMO configuration with continuous flow centrifugal pumps like CentriMag®, Rotaflow ®) or occasionally with LVADs placed on the right side. Recently the Impella RP® and ProtekDuo®, percutaneously placed pumps with inflow in the inferior vena cava & right atrium respectively and outflow in pulmonary artery, have become available as less invasive options, for short term RV support. The Syncardia® is the only approved total artificial heart system currently in use; however various biventricular, total heart systems (e.g. BiVACOR®) in development show promise. Mechanical circulatory devices provide attractive, viable, physiologically plausible ventricular support options that can be used effectively in carefully selected patients.

EKG for cardiology Board review

Abdelkader Almanfi

Estrategias para organoproteccion farmacológica durante la circulación extrac...

Miguel Ayala

Este documento describe estrategias farmacológicas para la protección de órganos durante la circulación extracorpórea. Se discuten los mecanismos de daño por isquemia y reperfusión en el corazón, cerebro y riñones. Varios fármacos se han estudiado como inhibidores de PARP, MMP y la bomba sodio-hidrógeno para reducir la disfunción de órganos. Estos fármacos apuntan a procesos como la acumulación de calcio, depleción de ATP y la inflamación, los

লাইফ স্টাইল ও স্বাস্থ্য

Subhanjan Das

What's hot

LVAD in India, LVAD Implantation in India, LVAD II Final Output 20/10/2015

Dr. Kewal Krishan

Wrok flow of Cath lab Process

Kuldeep singh

Vad presentatioin

EMSMedic79

LVADS

Anirudh Allam

16:05 Bufe - Learning to stop and to stage CTO PCI

Lvad vijayanand

Protect Af Holmes2

Lvad

Application of MCS for the Treatment of Advanced Heart Failure

faminteractive

Mechanical circulatory support

Hristo Rahman

Understanding the Translational Value of PV Loops from Mouse to Man

InsideScientific

The artificially prepared heart

Naveen Dasarapu

Ventricular Assist Devices

SMACC Conference

Outcomes of left ventricular assist device implantation stratifiedby psychoso...

Andri Andri

Ventricular assist devices

degnarog

Ventricular assist devices

Ela Maran

Advanced Cardiovascular Surgery Hybrid Operating Room (Nuts & Bolts)

Jacques Kpodonu,MD

Nwater machanical ovel assist devices

drucsamal

RVADs/LVADs and all things mechanical by Dr Jayshree Lavana

CICM 2019 Annual Scientific Meeting

EKG for cardiology Board review

Abdelkader Almanfi

What's hot (20)

LVAD in India, LVAD Implantation in India, LVAD II Final Output 20/10/2015

Wrok flow of Cath lab Process

Vad presentatioin

LVADS

16:05 Bufe - Learning to stop and to stage CTO PCI

Lvad vijayanand

Protect Af Holmes2

Lvad

Application of MCS for the Treatment of Advanced Heart Failure

Mechanical circulatory support

Understanding the Translational Value of PV Loops from Mouse to Man

The artificially prepared heart

Ventricular Assist Devices

Outcomes of left ventricular assist device implantation stratifiedby psychoso...

Ventricular assist devices

Advanced Cardiovascular Surgery Hybrid Operating Room (Nuts & Bolts)

Nwater machanical ovel assist devices

RVADs/LVADs and all things mechanical by Dr Jayshree Lavana

EKG for cardiology Board review

Viewers also liked

Estrategias para organoproteccion farmacológica durante la circulación extrac...

Miguel Ayala

লাইফ স্টাইল ও স্বাস্থ্য

Subhanjan Das

Geriatric care

Sadaf Shaikh ( P.T )

The document discusses geriatric care and the physiological and psychological changes associated with aging. It outlines common health problems among the elderly like cardiovascular, musculoskeletal, and neurological conditions. Prevention efforts aim to delay age-related problems through healthy habits, immunizations, and screenings. Rehabilitation services provide interventions to support functional abilities and caregivers. Both government and non-government organizations provide services to elderly populations.

Pt in geriatric

Shilpa Prajapati

This document provides an overview of physiotherapy for geriatric patients. It discusses assessing patients, setting goals, and therapeutic interventions. The assessment involves a full history, physical exam, and evaluation of functional status. Goals aim to improve mobility, strength, and quality of life. Therapeutic interventions may include range of motion, stretching, strengthening, aerobic exercise, and gait training exercises. Orthotics and reassessment are also discussed.

Geriatric pt

Subhanjan Das

Geriatrics is the branch of medicine focused on healthcare for the elderly. It aims to promote health and prevent/treat diseases and disabilities in older adults. Gerontology studies the process of aging. As people age, their skin, eyes, ears, kidneys, bones, nervous system, heart, lungs, and gastrointestinal system all undergo changes that can impact health. Common diseases in older adults include Alzheimer's, arthritis, cancer, cardiovascular disease, incontinence, and stroke. Geriatric physiotherapy addresses three main issues - deconditioning, cardiovascular diseases, and musculoskeletal problems. It focuses on reconditioning, exercise therapies, and addressing conditions like osteoporosis and osteoarthritis.

(2) burn rehabilitation

dr_nurul

The overall goal of burn rehabilitation is to return the patient to their pre-injury level of function with the best possible cosmetic outcome. Short term goals include assisting wound healing and preventing complications like contractures. Proper positioning is fundamental to burn rehabilitation as it prevents contractures, controls edema, prevents localized neuropathies, and helps maintain the elongated position of soft tissues. Positioning should be individualized but generally involve extending and abducting limbs to maintain burned tissues in their elongated state.

Cardiac Rehabilitation

Physical Medicine Institute

This document discusses cardiac rehabilitation and the effects of exercise. It describes 3 phases of cardiac rehabilitation: phase I focuses on early ambulation and low-intensity activities in the hospital; phase II involves incremental physical activity as an outpatient; and phase III emphasizes long-term community-based or home-based exercise. The benefits of habitual physical activity and exercise are summarized, including increased cardiac output and reduced heart rate, blood pressure, and mortality risks. Contraindications for exercise are also outlined.

Physiotherapy in burns

Thangamani Ramalingam

Physiotherapy plays an important role in the management of burn injuries. It focuses on positioning, splinting, and scar management to prevent contractures and promote wound healing. Positioning aims to maintain joints in functional positions opposite to the direction of potential contracture. Splinting is used during the acute inflammatory phase and following skin grafting to maintain positioning. Physiotherapy also addresses scar management through pressure therapy, stretching, and exercises to improve range of motion and function.

Defibrillators

Imran Sheikh

Defibrillators are devices that deliver an electrical shock to the heart to terminate life-threatening cardiac arrhythmias like ventricular fibrillation. They were first demonstrated on dogs in 1899 and first used on a human in 1947. There are several types including manual external defibrillators, automated external defibrillators (AEDs) found in public places, implantable cardioverter-defibrillators, and wearable defibrillators. AEDs can analyze the heart rhythm and instruct the user, who needs no training, on whether a shock is needed. Defibrillation aims to stop all cardiac electrical activity so the heart's natural pacemaker can resume normal rhythm, while cardioversion delivers synchronized shocks

Defibrillation, cardioversion and pacing

snich

This document discusses defibrillation, cardioversion, and pacing. It provides: 1) A brief history of defibrillation and its use for ventricular fibrillation and pulseless ventricular tachycardia. 2) An overview of cardioversion for treating unstable tachyarrhythmias with signs of low cardiac output, excessive heart rates, or chest pain. Synchronized cardioversion times shock delivery to the QRS complex. 3) Information on pacing for unstable bradyarrhythmias and symptomatic bradycardia, including complete heart block and Mobitz type II second-degree heart block.

Defibrillator (ppt)

Nitesh Kumar

Viewers also liked (11)

Estrategias para organoproteccion farmacológica durante la circulación extrac...

লাইফ স্টাইল ও স্বাস্থ্য

Geriatric care

Pt in geriatric

Geriatric pt

(2) burn rehabilitation

Cardiac Rehabilitation

Physiotherapy in burns

Defibrillators

Defibrillation, cardioversion and pacing

Defibrillator (ppt)

More from Miguel Ayala

Farmacologia Cardiovascular Diplomado Universidad Anahuac

Miguel Ayala

Basado en la información proporcionada, este paciente parece estar experimentando un shock séptico. Dada su hipotensión severa y alteración del estado de conciencia, recomendaría iniciar fluidoterapia agresiva con cristaloides y considerar vasopresores como norepinefrina para elevar la presión arterial. También sería importante tomar muestras de sangre y orina para cultivos y ampliar el espectro antibiótico inicial considerando la posibilidad de infección bacteriana. El monitoreo cercano del estado hemodinámico es crucial.

Shock inducido por endotelopatia

Tromboelastograma

Chagas

Manejo de delirium

Este documento resume estudios sobre el manejo farmacológico del delirium en pacientes después de cirugía cardíaca. Los antipsicóticos de segunda generación como la risperidona y la olanzapina pueden reducir la incidencia de delirium. La dexmedetomidina, un agonista alfa-2, puede proporcionar sedación y analgesia mientras reduce los días de delirium y la mortalidad en comparación con benzodiacepinas. El control adecuado del dolor y la suspensión oportuna de la sedación también son importantes para prevenir el

Miocardio no compacto en embarazo y trabeculaciones del VI

Miguel Ayala

Fisiopatologia de la hipertension arterial pulmonar

Miguel Ayala

Este documento describe la fisiopatología de la hipertensión arterial pulmonar. Se presentan los principales mecanismos como la vasoconstricción excesiva, la proliferación celular en la íntima y media de las arterias pulmonares, la fibrosis y la trombosis. Estos cambios conducen a remodelado vascular y aumento de la resistencia pulmonar total. Diversos factores como endotelinas, óxido nítrico, citocinas proinflamatorias y factores de crecimiento están involucrados y contribuyen al desbalance entre vas

More from Miguel Ayala (7)

Farmacologia Cardiovascular Diplomado Universidad Anahuac

Shock inducido por endotelopatia

Tromboelastograma

Chagas

Manejo de delirium

Miocardio no compacto en embarazo y trabeculaciones del VI

Fisiopatologia de la hipertension arterial pulmonar

Recently uploaded

Outbreak management including quarantine, isolation, contact.pptx

Pratik328635

June 2024 Oncology Cartoons By Dr Kanhu Charan Patro

Kanhu Charan

Post-Menstrual Smell- When to Suspect Vaginitis.pptx

FFragrant

Chapter 11 Nutrition and Chronic Diseases.pptx

Earlene McNair

8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx

Holistified Wellness

We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.

CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1

rishi2789

Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx

Dr. Rabia Inam Gandapore

CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf

rishi2789

Ketone bodies and metabolism-biochemistry

Dhayanithi C

Medical Quiz ( Online Quiz for API Meet 2024 ).pdf

Jim Jacob Roy

Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad

NephroTube - Dr.Gawad

- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ - Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0 - Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html - Link to NephroTube website: www.NephroTube.com - Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html

Acute Gout Care & Urate Lowering Therapy .pdf

Jim Jacob Roy

vonoprazan A novel drug for GERD presentation

Dr.pavithra Anandan

Cell Therapy Expansion and Challenges in Autoimmune Disease

Health Advances

There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities. In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions. Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved. Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.

DECLARATION OF HELSINKI - History and principles

anaghabharat01

Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx

Dr. Rabia Inam Gandapore

Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes

PsychoTech Services

CBL Seminar 2024_Preliminary Program.pdf

suvadeepdas911

Adhd Medication Shortage Uk - trinexpharmacy.com

reignlana06

The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com

Abortion PG Seminar Power point presentation

AksshayaRajanbabu

Recently uploaded (20)

Outbreak management including quarantine, isolation, contact.pptx

June 2024 Oncology Cartoons By Dr Kanhu Charan Patro

Post-Menstrual Smell- When to Suspect Vaginitis.pptx

Chapter 11 Nutrition and Chronic Diseases.pptx

8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx

CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1

Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx

CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf

Ketone bodies and metabolism-biochemistry

Medical Quiz ( Online Quiz for API Meet 2024 ).pdf

Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad

Acute Gout Care & Urate Lowering Therapy .pdf

vonoprazan A novel drug for GERD presentation

Cell Therapy Expansion and Challenges in Autoimmune Disease

DECLARATION OF HELSINKI - History and principles

Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx

Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes

CBL Seminar 2024_Preliminary Program.pdf

Adhd Medication Shortage Uk - trinexpharmacy.com

Abortion PG Seminar Power point presentation

Uso apropiado de DAI Resincro

1. Indicaciones de uso apropiado de DAI – Resincronizador Dr. Miguel Ayala León Residente de tercer año de cardiología

2. Figura 1 ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

3. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

4. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

5. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

6. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

7. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

8. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

9. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

10. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

11. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

12. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

13. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

14. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

15. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

16. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

17. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

18. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

19. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

20. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

21. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

22. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

23. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

24. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

25. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

26. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

27. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

28. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

29. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

30. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

31. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

32. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

33. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

34. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

35. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

36. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

37. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada

38. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

39. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

40. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

41. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

42. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada

43. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

44. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

45. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

46. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

47. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

48. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

49. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

50. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

51. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

52. 7 -9: apropiada/4-6: puede ser apropiada /1-3 raramente apropiada ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCM2013 Appropriate Use Criteria for Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy

Uso apropiado de DAI Resincro

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Viewers also liked

Viewers also liked (11)

More from Miguel Ayala

More from Miguel Ayala (7)

Recently uploaded

Recently uploaded (20)

Uso apropiado de DAI Resincro